Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
By Sara Merken
The Department of Justice is planning a review of prosecution policies that will likely create a clearer road map for federal prosecutors looking into health-care fraud, attorneys told Bloomberg Law.
A review of the Yates Memo, which set out guidance for prioritizing prosecution of individuals in corporate misconduct investigations, may provide clarity for attorneys about attorney-client privilege. The memo, named for former Deputy Attorney General Sally Yates, has implications for how the department assesses health-care fraud and similar allegations under the False Claims Act.
The Justice Department is aiming to formally incorporate existing instructions and policy guidance into official policy where appropriate, Deputy Attorney General Rod Rosenstein said.
DOJ policies should be accessible to those who are required to follow them, and enforcing policy through different memos is inefficient and ineffective, Rosenstein said at a New York University program on corporate compliance and enforcement Oct. 6.
The Justice Department is signaling its desire to implement a more holistic approach to white-collar crime policy, which could foster more consistent outcomes for individuals and companies in different districts, Gejaa Gobena, a former deputy chief of the DOJ criminal division’s fraud section and a Washington-based partner at Hogan Lovells, said
Harmonization of guideposts and memoranda would result in more comprehensive policy, he told Bloomberg BNA.
The DOJ is taking “concrete steps” to enhance federal prosecutions and civil actions for corporate fraud, using the guidelines published by Yates in September 2015, Rosenstein said at the conference.
There will likely be a nuanced shift to guideposts laid out in the Yates memo rather than a direct or complete repeal or revision, Michael Peregrine, a Chicago-based partner at McDermott, Will and Emery LLP, told Bloomberg Law. Peregrine is a member of a Bloomberg Law advisory board.
Discussion of the memo could be “one administration reacting against something that was put in place by another administration” that may not lead to significant differences in the enforcement posture, New York-based counsel Eric Fader, who represents health-care providers at Day Pitney LLP, told Bloomberg Law.
The DOJ’s review should resolve some of the “unintended consequences” of the Yates memo, Melissa Jampol, former assistant attorney in the U.S. attorney’s office for the District of New Jersey, told Bloomberg BNA. Jampol is a member of Epstein Becker Green’s health-care and life sciences and litigation practices in New York and Newark, N.J.
How corporations should respond to DOJ investigative inquiries for information on executives and individuals “remains a gray area for attorney client privilege” and deserves particular attention in a memo review, Jampol said.
The memo mandates full company cooperation in disclosing information about individuals allegedly involved in fraud if the organization expects to receive any cooperation credit for resolving investigations.
Companies and attorneys trying to understand the process would benefit from a more explicit breakdown of cooperation credit requirements, like that under the Foreign Corrupt Practices Act (FCPA) enforcement process, which lays out how much credit a company will receive in a settlement by a setting a percentage reduction, Jampol said.
Companies are concerned about whether withholding privileged client information results in forfeiting cooperation credit. A review of the memo should clarify the suggestion that the department alone makes the decision as to whether all relevant facts were provided in the investigation, Jampol added.
The clear and standardized metrics for conduct under the FCPA allow attorneys who represent corporate clients to have a better sense of the outcome of a case, Gobena said. The vague information disclosure requirements in the Yates memo created “more confusion than clarity” for defense attorneys, who would benefit from guideposts to help clients understand what to do from a compliance standpoint, Gobena said.
However, easing up on this aspect of the memo could potentially allow individuals to “hide behind the cloak of a corporation,” which would in effect “eviscerate the whole thrust of the Yates memo” of holding individuals accountable, Fader said.
The $155 million False Claims Act settlement ( United States ex rel. Delaney v. eClinicalWorks, LLC, D. Vt., No. 15-cv-95, settlement announced 5/31/17) with electronic health records vendor eClinicalWorks, which resolved allegations that the company and its three founders misrepresented the company’s software capabilities, “embodies the Yates memo,” Jampol said. A developer and a project manager also settled for $50,000 and $15,000, respectively, representing the attempt to hold all involved individuals accountable, she said.
The focus on individual accountability is likely to continue, while any changes to the Yates memo may soften the government’s regulation of corporations, Fader said.
The DOJ, which has recovered $60 million in actions against individuals under the False Claims Act in fiscal year 2017, is “trumpeting” the prosecution of individuals, Jampol said.
Rosenstein’s remarks on individual culpability match those of U.S. Attorney General Jeff Sessions at an ethics conference in April, and “the traditional Republican position of looking out for corporations” may continue in this administration, Fader said.
Any lenience in corporate regulation could cause companies and executives to “take advantage of the extra latitude,” he added.
Peregrine recommended that corporate boards develop strategies ahead of the potential that “executives will misperceive the message” of any DOJ policy modification and relax on compliance spending and diligence.
Boards should take the extra step to promote legal compliance programs amid the impending nuanced policy shift to signal to executives the necessity to maintain robust compliance programs and rigorous reviews of potential business risks, he said.
To contact the reporter on this story: Sara Merken in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Kendra Casey Plank at email@example.com
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)